Effect of trimetazidine on coronary flow and expression of inflammatory factors in AMI patients treated with PCI

Objective To study the effect of trimetazidine on coronary flow and expression of inflammatory factors in acute myocardial infarction (AMI) patients treated with percutaneous coronary intervention (PCI). Methods From September 2014 to September 2015, a total of 80 AMI patients were taken as the clinical research objects, and these patients were divided into observation group (40 cases) and control group (40 cases). Each group was treated with PCI and conventional treatment. On this basis, the observation group received additional trimetazidine in order to compare their effects of treatment, coronary flow and expression of inflammatory factors. Results After treatment, the left ventricular ejection fraction(LVEF)in the observation group was(50.29±4.27)%, which was significantly higher than that before treatment and the control group, and their differences were significant(P<0.05); the high sensitive C reactive protein(hs-CRP), interleukin-2 (IL-2) and interferon-γ(INF-γ) in the observation group were respectively (4.31±1.26)mg/L, (27.20±2.34)pg/ml and(237.31±28.89)pg/ml, which were significantly lower than those in the control group, and the differences were significant(P<0.05); the reperfusion rate in the observation group was 95%, which was significantly higher than that in the control group (80%), and the difference was significant(P<0.05). Conclusions Trimetazidine has satisfactory inhibition effect on myocardial damage in AMI patients treated with PCI, which can significantly improve the cardiac function and coronary flow, and inhibit the expression of inflammatory factors. Key words: Trimetazidine; Acute myocardial infarction; Percutaneous coronary intervention; Coronary flow; Inflammatory factor